Ralliant, Inc. (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians. These systems integrate tissue digestion, cell separation and cryogenic storage in a closed-system format, helping to maintain cell viability and sterility throughout the procedure. Ralliant’s offerings are designed to meet regulatory requirements and support a variety of clinical protocols.
Ralliant’s technologies are applied in orthopedic, aesthetic and wound-healing settings, where practitioners leverage the regenerative properties of SVF cells to support tissue repair and remodeling. By providing turnkey solutions for adipose-derived cell therapies, the company aims to expand the adoption of minimally invasive, autologous treatments and accelerate the translation of regenerative medicine research into routine clinical practice.
Headquartered in the United States, Ralliant distributes its systems through a combination of direct sales and strategic partnerships across North America, Europe and select international markets. The company’s leadership team combines expertise in medical device engineering, clinical research and commercial operations, positioning Ralliant to address evolving needs in cell-based therapy and point-of-care processing.
AI Generated. May Contain Errors.
